The proportion of patients who respond to tamoxifen depends on the characteristics of the tumour:
The efficacy of treatment varies with respect to pre- and post- menopausal women.
Bulbrook (BMJ editorial, 1996) suggests that more than five years' adjuvant therapy is not warranted because continuation of tamoxifen treatment would be unlikely to result in clinical benefit.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.